A Study to Assess the Safety and Efficacy of Nemolizumab (CD14152) in Subjects With Prurigo Nodularis (PN)
Phase of Trial: Phase II
Latest Information Update: 30 Sep 2019
Price : $35 *
At a glance
- Drugs Nemolizumab (Primary)
- Indications Prurigo nodularis
- Focus Therapeutic Use
- Sponsors Galderma
- 08 Feb 2019 Status changed from recruiting to completed.
- 25 Jan 2019 This trial ha been completed in Germany.
- 12 Dec 2018 This trial was completed in Austria and Poland (end date: 2018-09-26), according to European Clinical Trials Database.